US2019054049A1PendingUtilityA1
Activation of amp-protein activated kinase by oxaloacetate compounds
Est. expiryJun 22, 2030(~3.9 yrs left)· nominal 20-yr term from priority
Inventors:Alan B. Cash
A61K 31/198A61K 31/155A61K 31/194A61K 31/4439A61K 31/375A61K 45/06A61K 31/427
69
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to oxaloacetate compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds, preserving said compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, obesity, cardiovascular disease, Alzheimer's disease, and cancer.
Claims
exact text as granted — not AI-modified1 . A method for producing a beneficial lipid metabolism activating agent comprising the step of adding to a composition oxaloacetate, oxaloacetic acid, an oxaloacetate salt, alpha-ketoglutarate or aspartate.
2 . A method for producing an obesity suppressing agent comprising the step of adding to a composition oxaloacetate, oxaloacetic acid, an oxaloacetate salt, alpha-ketoglutarate or aspartate.
3 . A method for producing a diabetes preventing/ameliorating agent comprising the step of adding to a composition oxaloacetate, oxaloacetic acid, an oxaloacetate salt, alpha-ketoglutarate or aspartate.
4 . A method for producing a hepatic hypertrophy suppressing agent comprising the step of adding to a composition oxaloacetate, oxaloacetic acid, an oxaloacetate salt, alpha-ketoglutarate or aspartate.
5 . A method for producing a fatty liver suppressing agent comprising the step of adding to a composition oxaloacetate, oxaloacetic acid, an oxaloacetate salt, alpha-ketoglutarate or aspartate.
6 . A method for producing an exercise-substitutive agent comprising the step of adding to a composition oxaloacetate, oxaloacetic acid, an oxaloacetate salt, alpha-ketoglutarate or aspartate.
7 . A method for producing an athletic enhancing nutritional supplement comprising the step of adding to a composition oxaloacetate, oxaloacetic acid, an oxaloacetate salt, alpha-ketoglutarate or aspartate.
8 . A composition comprising oxaloacetate, oxaloacetic acid, an oxaloacetate salt, alpha-ketoglutarate or aspartate and an antidiabetic drug.
9 . The composition of claim 8 , wherein the antidiabetic drug is selected from the group consisting of rosiglitazone, troglitazone, pioglitazone, and metformin.Join the waitlist — get patent alerts
Track US2019054049A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.